《新股表現》海吉亞醫療(06078.HK)暗盤高開19%報22元
根據輝立交易平台顯示,下周一(29日)掛牌的海吉亞醫療(06078.HK)暗盤高開19%報22元獲承接,最高見24.5元,現造23.55元,較上市價18.5元,高27%,成交暫為56萬股。
根據弗若斯特沙利文資料,按2019年放療相關服務產生收入計,海吉亞是內地最大腫瘤醫療集團。是次來港上市共發售1.2億股,並已引入包括高瓴資本、奧博資本及南方基金等9名基石投資者,合共認購5,990.36萬股,其中10%公開發售獲逾607倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅8.8%,股份以招股範圍(17-18.5元)上限定價,料集資淨額約20.72億元,主要用作升級現有醫院和設立4間新醫院及收購醫院等。上市聯席保薦人分別為大摩及海通國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.